PIROVANO, MARTA
PIROVANO, MARTA
Universita' degli Studi di MILANO
How to deal with renal toxicities from immune-based combination treatments in metastatic renal cell carcinoma. A nephrological consultation for Oncologists
2024 M. Tucci, L. Cosmai, M. Pirovano, I. Campisi, R. Sartò Giulia Vanessa, C. Porta, M. Gallieni, P. Messa
Osimertinib in a patient with end-stage kidney disease not on hemodialysis
2024 M. Pirovano, A. Luciani, G.V. Re Sartò, A. Bramati, L. Cosmai
Letter to the Editor: Tumor Lysis Syndrome During Selpercatinib Treatment in a Patient with Medullary Thyroid Cancer
2023 S. De Leo, M. Trevisan, G.V. Re Sartò, C. Moneta, M. Pirovano, C. Colombo, L. Cosmai, L. Fugazzola
IL-8 and its role as a potential biomarker of resistance to anti-angiogenic agents and immune checkpoint inhibitors in metastatic renal cell carcinoma
2022 M. Rizzo, L. Varnier, G. Pezzicoli, M. Pirovano, L. Cosmai, C. Porta
Erdafitinib in locally advanced/metastatic urothelial carcinoma with certain FGFR genetic alterations
2022 A. Franza, M. Pirovano, P. Giannatempo, L. Cosmai
Treatment of acute kidney injury in cancer patients
2022 P. Braet, G.V.R. Sartò, M. Pirovano, B. Sprangers, L. Cosmai
L’immunoterapia nel tumore del rene: com’è cambiata e quali sono le sfide per il Nefrologo – focus su pembrolizumab [Immunotherapy in kidney cancer: how it has changed and what are the challenges for the nephrologist - focus on pembrolizumab]
2021 L. Cosmai, M. Pirovano, G.V. Re Sarto, M.A. Gallieni